Molecular Imaging in Urologic Surgery

Urologic Clinics of North America

Volumn 36, Issue 2, 2009, Pages 125-132

  Gee, Michael S ^a   Harisinghani, Mukesh G ^a   Tabatabaei, Shahin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

MRI; Optical imaging; Radiology

Indexed keywords

NANOPARTICLE;

BLADDER CANCER; CANCER STAGING; CELL FUNCTION; DIAGNOSTIC IMAGING; GERM CELL TUMOR; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; LYMPHOTROPIC NANOPARTICLE ENHANCED MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL COHERENCE TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UROLITHIASIS; UROLOGIC SURGERY;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NANOPARTICLES; POSITRON-EMISSION TOMOGRAPHY; SURGERY, COMPUTER-ASSISTED; TOMOGRAPHY, OPTICAL COHERENCE; UROLOGIC DISEASES;

EID: 65249112717     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2009.02.007     Document Type: Review

References (40)

1. Nascimento R.G., Coleman J., and Solomon S.B. Current and future imaging for urologic interventions. Curr Opin Urol 18 (2008) 116-121
2. Weissleder R., and Ntziachristos V. Shedding light onto live molecular targets. Nat Med 9 (2003) 123-128
3. Weissleder R., and Mahmood U. Molecular imaging. Radiology 219 (2001) 316-333
4. Phelps M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 97 (2000) 9226-9233
5. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 4 (2004) 891-899
6. Salminen E., Hogg A., Binns D., et al. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 41 (2002) 425-429
7. Sung J., Espiritu J.I., Segall G.M., et al. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int 92 (2003) 24-27
8. Effert P.J., Bares R., Handt S., et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155 (1996) 994-998
9. Hofer C., Laubenbacher C., Block T., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36 (1999) 31-35
10. Margolis D.J., Hoffman J.M., Herfkens R.J., et al. Molecular imaging techniques in body imaging. Radiology 245 (2007) 333-356
11. Kotzerke J., Prang J., Neumaier B., et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27 (2000) 1415-1419
12. Yamaguchi T., Lee J., Uemura H., et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 32 (2005) 742-748
13. Powles T., Murray I., Brock C., et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 51 (2007) 1511-1520 [discussion: 1520-11]
14. Ahlstrom H., Malmstrom P.U., Letocha H., et al. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 37 (1996) 180-185
15. Weissleder R., Elizondo G., Wittenberg J., et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175 (1990) 489-493
16. Kurhanewicz J., Vigneron D.B., Nelson S.J., et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 45 (1995) 459-466
17. Bremer C., Ntziachristos V., and Weissleder R. Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol 13 (2003) 231-243
18. Huang D., Swanson E.A., Lin C.P., et al. Optical coherence tomography. Science 254 (1991) 1178-1181
19. Pan Y., Lavelle J.P., Bastacky S.I., et al. Detection of tumorigenesis in rat bladders with optical coherence tomography. Med Phys 28 (2001) 2432-2440
20. Jaffer F.A., and Weissleder R. Molecular imaging in the clinical arena. JAMA 293 (2005) 855-862
21. Ntziachristos V., Bremer C., and Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 13 (2003) 195-208
22. Wilson C.B., Young H.E., Ott R.J., et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 22 (1995) 508-513
23. Albers P., Bender H., Yilmaz H., et al. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 53 (1999) 808-811
24. De Santis M., Becherer A., Bokemeyer C., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22 (2004) 1034-1039
25. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
26. Li C.S., Harisinghani M.G., Lin W.C., et al. Enhancement characteristics of ultrasmall superparamagnetic iron oxide particle within the prostate gland in patients with primary prostate cancer. J Comput Assist Tomogr 32 (2008) 523-528
27. Deserno W.M., Harisinghani M.G., Taupitz M., et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 233 (2004) 449-456
28. Freedland S.J., and Dekernion J.B. Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma. Rev Urol 5 (2003) 191-195
29. Pantuck A.J., Zisman A., Dorey F., et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169 (2003) 2076-2083
30. Blom J.H., van Poppel H., Marechal J.M., et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 36 (1999) 570-575
31. Guimaraes A.R., Tabatabei S., Dahl D., et al. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology 71 (2008) 708-712
32. 3) spatial resolution. Radiology 198 (1996) 795-805
33. Stamey T.A., McNeal J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999) 1395-1400
34. Coakley F.V., Kurhanewicz J., Lu Y., et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223 (2002) 91-97
35. Figueiredo J.L., Passerotti C.C., Sponholtz T., et al. A novel method of imaging calcium urolithiasis using fluorescence. J Urol 179 (2008) 1610-1614
36. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51 (2007) 137-149 [discussion: 149-51]
37. Lerner S.P., Goh A.C., Tresser N.J., et al. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology 72 (2008) 133-137
38. Johannsen M., Florcken A., Bex A., et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol (2008 Oct 18) [Epub ahead of print]
39. Black P.C., and Dinney C.P. Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev 26 (2007) 623-634
40. Sheth R.A., Upadhyay R., Weissleder R., et al. Real-time multichannel imaging framework for endoscopy, catheters, and fixed geometry intraoperative systems. Mol Imaging 6 (2007) 147-155